{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:50:12Z","timestamp":1772203812342,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/51994\/2012"],"award-info":[{"award-number":["SFRH\/BD\/51994\/2012"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","award":["NPRP8-2297-3-494"],"award-info":[{"award-number":["NPRP8-2297-3-494"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tumor cells have evolved complex strategies to escape immune surveillance, a process which involves NK cells and T lymphocytes, and various immunological factors. Indeed, tumor cells recruit immunosuppressive cells [including regulatory T-cells (Treg), myeloid-derived suppressor cells (MDSC)] and express factors such as PD-L1. Molecularly targeted therapies, such as imatinib, have off-target effects that may influence immune function. Imatinib has been shown to modulate multiple cell types involved in anti-cancer immune surveillance, with potentially detrimental or favorable outcomes. Imatinib and other tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) have dramatically changed disease course. Our study aimed to characterize the different populations of the immune system in patients with CML affected by their treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty-one patients with CML [33 treated with TKIs and 8 with TKIs plus interferon (IFN)-\u03b1] and 20 controls were enrolled in the present study. Peripheral blood populations of the immune system [referred to as the overview of immune system (OVIS) panel, Treg\u00a0cells and MDSCs] and PD-1 expression were evaluated\u00a0by flow cytometry. The immunological profile was assessed using the mRNA Pan-Cancer Immune Profiling Panel and a NanoString nCounter FLEX platform.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients receiving combination therapy (TKIs\u2009+\u2009IFN-\u03b1) had lower numbers of lymphocytes, particularly T cells [838\/\u00b5L (95% CI 594\u20131182)] compared with healthy controls [1500\/\u00b5L (95% CI 1207 \u2013 1865), p\u2009=\u20090.017]. These patients also had a higher percentage of Treg (9.1%) and CD4<jats:sup>+<\/jats:sup>PD-1<jats:sup>+<\/jats:sup>cells (1.65%) compared with controls [Treg (6.1%) and CD4<jats:sup>+<\/jats:sup>\/PD-1<jats:sup>+<\/jats:sup>(0.8%); p\u2009\u2264\u20090.05]. Moreover, patients treated with TKIs had more Mo-MDSCs (12.7%) whereas those treated with TKIs\u2009+\u2009IFN-\u03b1 had more Gr-MDSC (21.3%) compared to controls [Mo-MDSC (11.4%) and Gr-MDSC (8.48%); p\u2009\u2264\u20090.05]. CD56<jats:sup>bright<\/jats:sup>NK cells, a cell subset endowed with immune-regulatory properties, were increased in patients receiving TKIs plus IFN-\u03b1 compared with those treated with TKIs alone. Interestingly, serum IL-21 was significantly lower in the TKIs plus IFN-\u03b1 cohort. Within the group of patients treated with TKI monotherapy, we observed that individuals receiving 2nd generation TKIs had lower percentages of CD4<jats:sup>+<\/jats:sup>Treg (3.63%) and Gr-MDSC (4.2%) compared to patients under imatinib treatment (CD4<jats:sup>+<\/jats:sup>Treg 6.18% and Gr-MDSC 8.2%), but higher levels of PD-1-co-expressing CD4<jats:sup>+<\/jats:sup>cells (1.92%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest that TKIs in combination with IFN-\u03b1 may promote an enhanced immune suppressive state.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-019-02194-x","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T10:03:14Z","timestamp":1578045794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-\u03b1"],"prefix":"10.1186","volume":"18","author":[{"given":"Raquel","family":"Alves","sequence":"first","affiliation":[]},{"given":"Stephanie E. B.","family":"McArdle","sequence":"additional","affiliation":[]},{"given":"Jayakumar","family":"Vadakekolathu","sequence":"additional","affiliation":[]},{"given":"Ana Cristina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Freitas-Tavares","sequence":"additional","affiliation":[]},{"given":"Am\u00e9lia","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Antonio M.","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Ana Bela","family":"Sarmento-Ribeiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-7375","authenticated-orcid":false,"given":"Sergio","family":"Rutella","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"2194_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2194_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrclinonc.2015.193","volume":"13","author":"AJ Innes","year":"2016","unstructured":"Innes AJ, Milojkovic D, Apperley JF. Allogeneic transplantation for CML in the TKI era: striking the right balance. Nat Rev Clin Oncol. 2016;13:79\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"2194_CR3","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186\u201393.","journal-title":"Lancet Haematol"},{"key":"2194_CR4","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"2194_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"2194_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/leu.2015.45","volume":"29","author":"A Burchert","year":"2015","unstructured":"Burchert A, Saussele S, Eigendorff E, Muller MC, Sohlbach K, Inselmann S, Schutz C, Metzelder SK, Ziermann J, Kostrewa P, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015;29:1331\u20135.","journal-title":"Leukemia"},{"key":"2194_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12929-017-0317-0","volume":"24","author":"C-F Lin","year":"2017","unstructured":"Lin C-F, Lin C-M, Lee K-Y, Wu S-Y, Feng P-H, Chen K-Y, Chuang H-C, Chen C-L, Wang Y-C, Tseng P-C, Tsai T-T. Escape from IFN-\u03b3-dependent immunosurveillance in tumorigenesis. J Biomed Sci. 2017;24:10.","journal-title":"J Biomed Sci"},{"key":"2194_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253.","journal-title":"Nat Rev Immunol"},{"key":"2194_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","volume":"14","author":"L Christiansson","year":"2015","unstructured":"Christiansson L, S\u00f6derlund S, Mangsbo S, Hjorth-Hansen H, H\u00f6glund M, Markev\u00e4rn B, Richter J, Stenke L, Mustjoki S, Loskog A, Olsson-Str\u00f6mberg U. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015;14:1181\u201391.","journal-title":"Mol Cancer Ther"},{"key":"2194_CR10","doi-asserted-by":"publisher","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, S\u00f6derlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Str\u00f6mberg U, Loskog ASI. Increased level of myeloid-derived suppressor cells, Programmed Death Receptor Ligand 1\/Programmed Death Receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE. 2013;8:e55818.","journal-title":"PLoS ONE"},{"key":"2194_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.14694\/EDBK_156572","volume":"36","author":"V Velcheti","year":"2016","unstructured":"Velcheti V, Schalper K. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book. 2016;36:298\u2013308.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2194_CR12","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Sch\u00fcrch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia\u2014specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114:1528\u201336.","journal-title":"Blood"},{"key":"2194_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14737159.2017.1381560","volume":"17","author":"D Zafeiris","year":"2017","unstructured":"Zafeiris D, Vadakekolathu J, Wagner S, Pockley AG, Ball GR, Rutella S. Discovery and application of immune biomarkers for hematological malignancies. Expert Rev Mol Diagn. 2017;17:983\u20131000.","journal-title":"Expert Rev Mol Diagn"},{"key":"2194_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","volume":"13","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G. Immunological off-target effects of imatinib. Nat Rev Clin Oncol. 2016;13:431\u201346.","journal-title":"Nat Rev Clin Oncol"},{"key":"2194_CR15","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1084\/jem.20130875","volume":"210","author":"MJ Cavnar","year":"2013","unstructured":"Cavnar MJ, Zeng S, Kim TS, Sorenson EC, Ocuin LM, Balachandran VP, Seifert AM, Greer JB, Popow R, Crawley MH, et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med. 2013;210:2873\u201386.","journal-title":"J Exp Med"},{"key":"2194_CR16","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/sj.leu.2403474","volume":"18","author":"N Boissel","year":"2004","unstructured":"Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, Degos L, Dombret H, Toubert A, Rea D. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia. 2004;18:1656\u201361.","journal-title":"Leukemia"},{"key":"2194_CR17","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.leu.2403933","volume":"19","author":"H Gao","year":"2005","unstructured":"Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 2005;19:1905\u201311.","journal-title":"Leukemia"},{"key":"2194_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","volume":"122","author":"H de Lavallade","year":"2013","unstructured":"de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227\u201338.","journal-title":"Blood"},{"key":"2194_CR19","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","volume":"111","author":"CI Chen","year":"2008","unstructured":"Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood. 2008;111:5342\u20139.","journal-title":"Blood"},{"key":"2194_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI21102","volume":"114","author":"C Borg","year":"2004","unstructured":"Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;114:379\u201388.","journal-title":"J Clin Invest"},{"key":"2194_CR21","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1158\/0008-5472.CAN-08-3807","volume":"69","author":"C Menard","year":"2009","unstructured":"Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69:3563\u20139.","journal-title":"Cancer Res"},{"key":"2194_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/nm.2438","volume":"17","author":"VP Balachandran","year":"2011","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094\u2013100.","journal-title":"Nat Med"},{"key":"2194_CR23","doi-asserted-by":"publisher","first-page":"e101848","DOI":"10.1371\/journal.pone.0101848","volume":"9","author":"C Giallongo","year":"2014","unstructured":"Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS ONE. 2014;9:e101848.","journal-title":"PLoS ONE"},{"key":"2194_CR24","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","volume":"181","author":"N Larmonier","year":"2008","unstructured":"Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E. Imatinib mesylate inhibits CD4+\u2009CD25+\u2009regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol. 2008;181:6955\u201363.","journal-title":"J Immunol"},{"key":"2194_CR25","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3389\/fimmu.2018.02028","volume":"9","author":"GA Foulds","year":"2018","unstructured":"Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, Nagarajan D, Reeder S, Johnson C, Hood S, Moseley PM, Chan SYT, Pockley AG, et al. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Front Immunol. 2018;9:2028.","journal-title":"Front Immunol"},{"key":"2194_CR26","doi-asserted-by":"crossref","unstructured":"Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol. 2011;Chapter 25:Unit25B 10.","DOI":"10.1002\/0471142727.mb25b10s94"},{"key":"2194_CR27","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-15-0262","volume":"75","author":"MH Veldman-Jones","year":"2015","unstructured":"Veldman-Jones MH, Brant R, Rooney C, Geh C, Emery H, Harbron CG, Wappett M, Sharpe A, Dymond M, Barrett JC, et al. Evaluating robustness and sensitivity of the nanoString Technologies nCounter platform to enable multiplexed gene expression analysis of clinical samples. Cancer Res. 2015;75:2587\u201393.","journal-title":"Cancer Res"},{"key":"2194_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano A. nCounter PanCancer Immune Profiling Panel (NanoString Technologies Inc, Seattle, WA). J Immunother Cancer. 2015;3:42.","journal-title":"J Immunother Cancer"},{"key":"2194_CR29","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1084\/jem.194.12.1711","volume":"194","author":"J Geginat","year":"2001","unstructured":"Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med. 2001;194:1711\u20139.","journal-title":"J Exp Med"},{"key":"2194_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1200\/JCO.2018.36.5_suppl.50","volume":"36","author":"S Rutella","year":"2018","unstructured":"Rutella S, Vadakekolathu J, Altmann H, Patel T, Reeder S, Liang Y, Schmitz M, Hood T, Danaher P, Warren S, et al. Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology. J Clin Oncol. 2018;36:50.","journal-title":"J Clin Oncol"},{"key":"2194_CR31","first-page":"3942","volume":"130","author":"J Vadakekolathu","year":"2017","unstructured":"Vadakekolathu J, Patel T, Reeder S, Schaarschmidt H, Schmitz M, Bornh\u00e4user M, Warren SE, Hood T, Danaher P, Cesano A, et al. Immune gene expression profiling in children and adults with acute myeloid leukemia identifies distinct phenotypic patterns. Blood. 2017;130:3942.","journal-title":"Blood"},{"key":"2194_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher P, Warren S, Dennis L, D\u2019Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5:18.","journal-title":"J Immunother Cancer"},{"key":"2194_CR33","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/jcmm.13326","volume":"22","author":"C Giallongo","year":"2018","unstructured":"Giallongo C, Parrinello NL, La Cava P, Camiolo G, Romano A, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, et al. Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. J Cell Mol Med. 2018;22:1070\u201380.","journal-title":"J Cell Mol Med"},{"key":"2194_CR34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267\u201384.","journal-title":"Genes Dev"},{"key":"2194_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40291-016-0208-1","volume":"20","author":"MAM Ali","year":"2016","unstructured":"Ali MAM. Chronic myeloid leukemia in the era of tyrosine kinase inhibitors: an evolving paradigm of molecularly targeted therapy. Mol Diagn Ther. 2016;20:315\u201333.","journal-title":"Mol Diagn Ther"},{"key":"2194_CR36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"2194_CR37","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Sau\u00dfele","year":"2016","unstructured":"Sau\u00dfele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638.","journal-title":"Leukemia"},{"key":"2194_CR38","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.11223","volume":"97","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, et al. Complete cytogenetic and molecular responses to interferon-\u03b1-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033\u201341.","journal-title":"Cancer"},{"key":"2194_CR39","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511\u201321.","journal-title":"N Engl J Med"},{"key":"2194_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12185-012-1116-8","volume":"96","author":"P Rohon","year":"2012","unstructured":"Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol. 2012;96:1\u20139.","journal-title":"Int J Hematol"},{"key":"2194_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8:469.","journal-title":"Front Immunol"},{"key":"2194_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2298\/VSP1504342S","volume":"72","author":"I Stanojevic","year":"2015","unstructured":"Stanojevic I, Gavevic M, Jovic M, Mijugkovic Z, Zevevic R, Zolotarevski L, Jaukovic L, Rajovic M, Novakovic M, Binic I, Vojvodic D. Interferon alpha-induced reduction in the values of myeloid-derived suppressor cells in melanoma patients. Vojnosanit Pregl. 2015;72:342\u20139.","journal-title":"Vojnosanit Pregl"},{"key":"2194_CR43","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1158\/0008-5472.CAN-12-3788","volume":"73","author":"N Bacher","year":"2013","unstructured":"Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, Bopp T, Zechner U, Merten L, Becker C, Steinbrink K. Interferon-\u03b1 suppresses cAMP to disarm human regulatory T cells. Cancer Res. 2013;73:5647\u201356.","journal-title":"Cancer Res"},{"key":"2194_CR44","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","volume":"196","author":"T Michel","year":"2016","unstructured":"Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, Zimmer J. Human CD56bright NK cells: an update. J Immunol. 2016;196:2923\u201331.","journal-title":"J Immunol"},{"key":"2194_CR45","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1172\/JCI90387","volume":"127","author":"JA Wagner","year":"2017","unstructured":"Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017;127:4042\u201358.","journal-title":"J Clin Invest"},{"key":"2194_CR46","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1212\/NXI.0000000000000065","volume":"2","author":"J Elkins","year":"2015","unstructured":"Elkins J, Sheridan J, Amaravadi L, Riester K, Selmaj K, Bielekova B, Parr E, Giovannoni G. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e65.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2194_CR47","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1177\/1352458511414755","volume":"17","author":"JP Sheridan","year":"2011","unstructured":"Sheridan JP, Zhang Y, Riester K, Tang MT, Efros L, Shi J, Harris J, Vexler V, Elkins JS. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler. 2011;17:1441\u20138.","journal-title":"Mult Scler"},{"key":"2194_CR48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2172-10-46","volume":"10","author":"G Bonanno","year":"2009","unstructured":"Bonanno G, Mariotti A, Procoli A, Corallo M, Scambia G, Pierelli L, Rutella S. Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells. BMC Immunol. 2009;10:46.","journal-title":"BMC Immunol"},{"key":"2194_CR49","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, et al. Natural killer cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368\u201377.","journal-title":"Haematologica"},{"key":"2194_CR50","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Stromberg U, Schlums H, Guilhot J, Bruck O, Lahteenmaki H, Kasanen T, Koskenvesa P, Soderlund S, Hoglund M, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108\u201316.","journal-title":"Leukemia"},{"key":"2194_CR51","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436.","journal-title":"Nature"},{"key":"2194_CR52","first-page":"997","volume":"32","author":"H Onishi","year":"2012","unstructured":"Onishi H, Morisaki T, Katano M. Immunotherapy approaches targeting regulatory T cells. Anticancer Res. 2012;32:997\u20131003.","journal-title":"Anticancer Res"},{"key":"2194_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/biomedicines6010025","volume":"6","author":"A Schnell","year":"2018","unstructured":"Schnell A, Schmidl C, Herr W, Siska PJ. The peripheral and intratumoral immune cell landscape in cancer patients: a proxy for tumor biology and a tool for outcome prediction. Biomedicines. 2018;6:25.","journal-title":"Biomedicines"},{"key":"2194_CR54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2567.2010.03280.x","volume":"131","author":"A Golding","year":"2010","unstructured":"Golding A, Rosen A, Petri M, Akhter E, Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology. 2010;131:107\u201317.","journal-title":"Immunology"},{"key":"2194_CR55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/vaccines4040036","volume":"4","author":"V Umansky","year":"2016","unstructured":"Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines. 2016;4:36.","journal-title":"Vaccines"},{"key":"2194_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2015.00107","volume":"5","author":"C Giallongo","year":"2015","unstructured":"Giallongo C, Parrinello N, Brundo MV, Raccuia SA, Di Rosa M, La Cava P, Tibullo D. Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol. 2015;5:107.","journal-title":"Front Oncol"},{"key":"2194_CR57","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.4049\/jimmunol.1502638","volume":"198","author":"K Taleb","year":"2017","unstructured":"Taleb K, Auffray C, Villefroy P, Pereira A, Hosmalin A, Gaudry M, Le Bon A. Chronic type I IFN is sufficient to promote immunosuppression through accumulation of myeloid-derived suppressor cells. J Immunol. 2017;198:1156.","journal-title":"J Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-02194-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-02194-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-02194-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T17:20:42Z","timestamp":1722273642000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-02194-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-02194-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research project was approved by the Institutional Review Board, Medical School of the University of Coimbra, Coimbra, Portugal. Written informed consent was obtained from each participant before enrollment into the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}